Objective: This study aims to evaluate outcomes associated with different P2Y12 agents in Saphenous Vein graft (SVG) percutaneous coronary intervention (PCI).
greater foam cell and inflammatory cell components and less welldeveloped fibrous caps than in native coronary disease [2] . Such features render SVG lesions more prone to distal embolization during PCI and, in acute presentations, more often associated with a heavy thrombus burden [3] . SVG intervention represents an important component of the recent dual antiplatelet therapy (DAPT) score for predicting future ischemic risk [4] . Hence periprocedural myocardial ischemia and infarction are major concerns, notwithstanding use of strategies to reduce these, such as embolic protection devices [5, 6] and/or vasoactive drugs [7] .
The role of potent platelet inhibition in ameliorating these problems is not clear. For example, intravenous glycoprotein IIb/IIIa inhibitor (GPI) use has not been associated with same benefits in SVG PCI as seen in native coronary intervention [8] , except possibly when used in conjunction with embolic protection [9] . More recently, the potent selective P2Y12 agents, Ticagrelor and Prasugrel, have become available and show a reduction in ischemic endpoints following PCI for acute coronary syndromes (ACSs), compared with Clopidogrel [10, 11] . There was also a reduction in all-cause mortality with Ticagrelor in this setting. This has led to increasing use of these agents in PCI settings associated with higher ischemic risk. Outside their role in PCI, potent P2Y12 blockade is also seen to improve graft patency following coronary artery bypass graft (CABG) surgery [12] . However, there are little data regarding possible benefits of potent P2Y12 inhibitor use in the specific setting of SVG PCI for ACS. The data cited above in relation to GPIs caution against extrapolation from nonSVG studies. In the PLATO study, the outcomes in postCABG patients with Ticagrelor use did not appear to differ from the overall study findings [13] -however this was a posthoc analysis in which the usual caveats regarding potentially unbalanced comparison groups apply. Additionally, outcomes in that paper were not separated based on whether PCI was undertaken in a bypass graft or native vessel, further limiting interpretation. No equivalent subgroup evaluation is available for Prasugrel from TRITON-TIMI 38.
Given the paucity of evidence to guide practice with potent antiplatelet drugs in SVG PCI, we undertook an analysis using the UK British Cardiovascular Interventional Society PCI database. Our aim was to explore outcomes associated with the use of the newer antiplatelet agents Prasugrel or Ticagrelor in the setting of SVG PCI for ACS.
| M E TH ODS

| Study design and data collection
The BCIS database records information on PCI procedures in the UK and the data collection is managed by the National Institute of Cardiovascular Outcomes Research [14] [15] [16] . A retrospective analysis was performed of all participants with PCI to vein grafts and receipt of dual 
| Variables, exposures, and outcomes
Data on participants' demographics (age, sex, body mass index and smoking status) and comorbidities (diabetes, hypertension, hypercholesterolemia, previous myocardial infarction, previous stroke, peripheral vascular disease, renal disease, valvular heart disease) were collected.
Additional information was collected on previous CABG, previous PCI, radial access, cardiogenic shock, circulatory support, receipt of ventilation, diagnosis, GPI use, warfarin, thrombolysis, embolic protection device, PCI to nonvein graft vessel, use of drug eluting stent and year of PCI procedure. The primary exposure variable was Clopidogrel, Prasugrel, and Ticagrelor and the outcome variables were 30-day and 1 year mortality, and in-hospital major adverse cardiovascular events (defined by in-hospital death, in-hospital NonQ wave and Q wave myocardial infarction, reinfarction, emergency CABG and reintervention PCI).
| Statistical methods
Statistical analysis was performed on Stata v14 (Stata Corp., Texas).
Participants with missing data for 30-day mortality, antiplatelet therapy, CABG and patients who did not have PCI to vein graft were excluded. A flow diagram of participant inclusion is shown in Figure 1 .
Descriptive statistics of included variables were presented as mean 6 SD for continuous data and percentages for categorical data according to antiplatelet therapy (Clopidogrel, Prasugrel, or Ticagrelor). The clinical characteristics of the three groups were compared using ANOVA or Chi-squared tests for continuous or categorical variables, respectively.
Multiple imputations by chained equations were performed using mi impute chained function in Stata to generate 10 complete datasets. The imputed variables were age, sex, smoking, body mass index, diabetes, hypertension, hypercholesterolemia, previous myocardial infarction, previous stroke, peripheral vascular disease, renal failure, valvular heart disease, previous PCI, access site, cardiogenic shock, receipt of ventilation, GPI use, warfarin use, thrombolysis, embolic protection device use, PCI to nonveingraft vessels, drug eluting stent use, diagnosis, and year of PCI procedure. The outcomes were included in the imputation model (mortality at 30-days and 1-year, in-hospital major adverse cardiovascular events and in-hospital bleeding), but we did not predict the outcome since that makes no difference [17] . The extent of missing data is presented in Supporting Information Table S1 . The imputed FIGURE 1 Flow diagram of PCI procedures in England and Wales datasets were used to perform multiple logistic regressions (MLRs) to identify independent predictors of Clopidogrel, Prasugrel, and Ticagrelor use. MLRs were also used to identify how antiplatelet therapy affects risk of 30-day and 1-year mortality, in-hospital MACE and in-hospital bleeding. In addition, propensity score matching (PSM) methods were used to estimate adjusted risk estimates (using all covariates) for all pairwise antiplatelet group comparisons (Prasugrel vs. Clopidogrel, Ticagrelor vs. Clopidogrel, Ticagrelor vs. Prasugrel). This was performed using the teffects psmatch function in Stata to estimate the average treatment effects while accounting for baseline differences across the groups. Estimates were aggregated across the 10 imputed datasets using Rubin's rules [18] . Using the standard setting for matching, a minimum of one neighbor was matched for all observations. Tolerance for the overlap assumption was set to 10 25 . Despite the marked difference in overall group sizes, the mean age and gender distribution was similar across groups. It is noteworthy that patient age range, body mass index and the frequency of previous CVA were similar between the different P2Y12 groups. Some important differences between the characteristics of the groups also merit specific mention. The predominant use of Prasugel was in the setting of STEMI whilst for Ticagrelor, use in NSTEMI/UA was most frequent. There was a higher proportion of radial access use in the patients receiving more potent P2Y12 blockers, which might be a time (i.e., year of treatment)-dependent effect. Greater use of embolic protection devices was seen with Ticagrelor, whilst use of adjunctive GPI was highest with Prasugrel. Table 2 , showing predictors of P2Y12 antiplatelet choice from multivariable analysis (MVA), indicates those which appear to be independently associated with their use. Whilst younger age appears as a predictor for both Prasugrel and Ticagrelor use, the odds ratio of around 1 indicates a very small effect size, as seen from the raw data in Figure 1 .
| R E SU LTS
Unadjusted data (Table 1 ) demonstrate a higher 30-day mortality associated with Prasugrel use compared with the other 2 agents, which was also observed for 1-year mortality. Recorded in-hospital MACE and major bleeding are very similar across groups. Given the marked differences in composition/clinical characteristics of the groups (as noted above), we undertook MVA. Tables 3 and 4 illustrate clinical outcomes when adjustment was made by use of MVA and by PSM, respectively. In the MVA, we observed a large effect estimate for lower 30-day mortality with Ticagrelor use, compared with Clopidogrel, although this did not reach statistical significance. No other significant differences for early mortality or in-hospital complications were noted from MVA. The matching success for our propensity score model is shown in Supporting Information Table S2 . As shown in Table 4 , there was no difference in outcomes comparing antiplatelet drugs.
| D ISC USSION
Vein graft PCI represents a distinct subset, for which patient outcomes remain inferior to those seen in native coronary disease. Hence a search for approaches to improve outcomes for patients with vein graft disease is important. Where practical, treatment of native disease in the territory of the diseased graft (rather than the graft itself) is now the preferred option. However, this is not always straightforward, particularly if this native coronary contains a complex chronic total occlusion or has diffuse severe disease. So SVG PCI will continue to be the favored revascularization option in a proportion of cases, and therefore defining an optimal anti-ischemic strategy in such cases remains important. There is currently a lack of trial evidence or observational data on the effect of potent specific P2Y12 receptor inhibition in SVG PCI. have influenced individual institutions' decisions in opting to switch to one or other P2Y12 blocker in high-risk ACS, and hence also (as a consequence) in the SVG PCI subset of these patients.
We observed higher use of radial access and of embolic protection devices with potent P2Y12 blockers that may have favored better outcomes with these agents in unadjusted analyses, although this effect was mitigated in the adjusted analyses once differences in baseline covariates were made. The markedly higher use of GPI seen with Prasugrel likely reflected the high proportion of STEMI cases in that group, where onset of antiplatelet action is most rapidly required. As noted earlier, the benefit of GPI in the setting of SVG PCI is equivocal (although its adverse impact on risk of bleeding is not).
Following MVA, we observed no significant differences for the potent P2Y12 blockers over Clopidogrel in SVG PCI for a number of clinically important endpoints. There are various potential explanations for this finding. Firstly, the pathophysiology of vein graft disease may lead to downstream debris during PCI that differs significantly in composition from that encountered with native coronary atheroma. Friable, foam-cell rich plaque might constitute the bulk of such debris and this could explain the lack of effect seen with both GPI and (in our present work) with potent oral P2Y12 blockers.
A second possibility is that a benefit with Ticagrelor or Prasugrel over Clopidogrel might actually exist but our study was underpowered to detect this, given (1) the relatively low patient numbers in the potent P2Y12 groups and (2) the modest event rates across all groups. This possibility is difficult to exclude fully and would require significantly larger numbers to clarify, although it is unlikely that an adequately powered randomized trial would ever be undertaken to investigate this. Furthermore, any clinical benefit with potent P2Y12 agents in SVG PCI may not be sufficient to be seen as a survival advantage but might produce a reduction in recurrent myocardial infarction or MACE.
Such an effect would not be detected outside the index hospital admission in this work. A third possibility for our present findings is that an anti-ischemic benefit exists with potent P2Y12 blockers but that any mortality benefit is offset by adverse effects from later (postdischarge) major bleeding. This is plausible, given the demographics of the potent P2Y12 groups, which contain subgroups known to be at higher risk of bleeding problems. Clarification of this issue would require more 
| Limitations
There are certain limitations in this work that apply to all observational and registry-based research. Most importantly, such studies cannot determine cause and effect and hence only associations can be identified. Additionally, conclusions drawn from these associations may be influenced by confounders that will not be 'visible' on the dataset (unmeasured confounding). These reflect variables which are not captured but which are related to both (nonblinded) treatment allocation and to outcome. Among these are factors such as frailty and noncardiovascular comorbidity [22, 23] . However, in this particular work, clinical assessment of frailty or multimorbidity would be expected to lead to use of Ticagrelor or Prasugrel in "less frail"/multimorbid patients overall; and hence any confounding in this regard should favor outcomes in the potent P2Y12 groups. Hence, it is unlikely that neutral effects on outcome found with these agents in our study are attributable to being disadvantaged by frailty as an unrecorded confounder. In addition, we did not have information on the age of the graft at time of PCI.
Although our analysis suggests no difference in outcomes for patients depending on choice of antiplatelet therapy, there may still be a difference depending on treatment but we are not able to detect it in the current study due to small sample size.
Another recognized limitation is that robust outcome tracking is currently available only for mortality. Clinical advantages with more potent antiplatelet agents may exist but may not be sufficient to appear as a mortality signal. In-hospital MACE and bleeding rates were available but a reliance on retrospective documentation at a centerlevel (rather than by robust linkage) is likely to contribute to low recorded event rates for these endpoints. Furthermore, out of hospital MACE and bleeding events are not captured on our dataset, unless fatal. Nevertheless despite such limitations, our study provides important new data around outcomes associated with newer P2Y12 agents in SVG PCI as there is unlikely to be an adequately powered RCT comparing outcomes for hard clinical endpoints and so should be considered best available evidence currently available.
| CON CL U S I ONS
Our study of real-world SVG PCI from the UK national registry shows no benefit in 30-day mortality, 1-year mortality or in-hospital complications for the newer, more potent, oral P2Y12 antiplatelet agents over Clopidogrel.
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